Rheumatoid Arthritis
📧 Sign up to get email alerts when something new happens for Rheumatoid Arthritis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Hulio (adalimumab) biosimilar with approvals across multiple inflammatory indications.
-
EMA approval · 2026-08-24EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) for multiple inflammatory diseases including rheumatoid arthritis and Crohn's disease.
-
EMA approval · 2026-08-21EMA Authorised: Tuyory — Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)
EMA authorised Tuyory from Chemical Works of Gedeon Richter Plc. for multiple indications including rheumatoid arthritis, juvenile arthritis…
-
EMA approval · 2026-08-20EMA Authorised: MabThera (rituximab) — Roche Registration GmbH
EMA authorization of MabThera (rituximab) for multiple indications including non-Hodgkin lymphoma, rheumatoid arthritis, and chronic lymphoc…
-
EMA approval · 2026-08-19EMA Authorised: Tyenne (tocilizumab) — Fresenius Kabi Deutschland GmbH
Tyenne (tocilizumab) has been authorised by the EMA for multiple indications including rheumatoid arthritis, cytokine release syndrome, juve…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-08-19EMA Authorised: Xeljanz (tofacitinib) — Pfizer Europe MA EEIG
Authorisation granted in the EU for Xeljanz (tofacitinib) for arthritis and rheumatoid conditions.
-
EMA approval · 2026-08-18EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
Amgevita (adalimumab) by Amgen Europe B.V. has been authorised by the EMA for multiple inflammatory diseases including arthritis, psoriatic …
-
EMA approval · 2026-08-13EMA Authorised: RoActemra (tocilizumab) — Roche Registration GmbH
RoActemra (tocilizumab) has been authorised by the European Medicines Agency for multiple indications including rheumatoid arthritis, juveni…
-
EMA approval · 2026-08-06EMA Authorised: MabThera (rituximab) — Roche Registration GmbH
EMA authorised MabThera (rituximab) by Roche Registration GmbH for multiple indications including non-Hodgkin lymphoma, rheumatoid arthritis…
-
EMA approval · 2026-08-06EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) from Fresenius Kabi Deutschland for multiple inflammatory diseases including rheuma…
-
EMA approval · 2026-08-05EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
EMA authorises Humira (adalimumab) for multiple inflammatory diseases across indications, confirming market authorization.
-
EMA approval · 2026-08-04EMA Authorised: Leflunomide medac (leflunomide) — medac Gesellschaft für klinische Spezialpräparate mbH
Authorised status for Leflunomide medac (leflunomide) intended for rheumatoid arthritis.
-
EMA approval · 2026-07-30EMA Authorised: Leflunomide ratiopharm (leflunomide) — Ratiopharm GmbH
Authorisation of Leflunomide Ratiopharm (leflunomide) for rheumatoid arthritis in the EU.
-
EMA approval · 2026-07-30EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
Biosimilar adalimumab (Hulio) has been authorised by EMA for multiple indications including hidradenitis suppurativa, psoriasis, uveitis, rh…
-
EMA approval · 2026-07-21EMA Authorised: Gobivaz (golimumab) — Advanz Pharma Limited
Authorised status for Gobivaz (golimumab) by Advanz Pharma Limited for multiple inflammatory diseases, expanding label in Europe.
-
EMA approval · 2026-07-17EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EU authorization of Hukyndra (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including rheumatoid arthritis and inf…
-
EMA approval · 2026-07-16EMA Authorised: Xeljanz (tofacitinib) — Pfizer Europe MA EEIG
EMA authorises Xeljanz (tofacitinib) for rheumatic arthritis under Pfizer Europe MA EEIG.
-
EMA approval · 2026-07-15EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG
Rinvoq (upadacitinib) has been authorised by the EMA for multiple inflammatory diseases including rheumatoid arthritis, psoriatic arthritis,…
-
EMA approval · 2026-07-13EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
Authorised status for Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory and autoimmune diseases.
-
EMA approval · 2026-07-13EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) for multiple inflammatory diseases, expanding the portfolio under Fresenius Kabi De…
-
EMA approval · 2026-07-01EMA Authorised: Gotenfia (golimumab) — Stada Arzneimittel AG
European Medicines Agency authorised Gotenfia (golimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including various form…
-
EMA approval · 2026-07-01EMA Authorised: Erelzi (etanercept) — Sandoz GmbH
Authorised status for Erelzi (etanercept) by Sandoz GmbH, expanding access to therapy for multiple inflammatory arthritis conditions.
-
EMA approval · 2026-06-15EMA Authorised: Tuyory — Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)
Tuyory has been authorised by the EMA for multiple indications including rheumatoid arthritis, juvenile arthritis, cytokine release syndrome…
-
EMA approval · 2026-06-12EMA Authorised: Fubelv — Biosimilar Collaborations Ireland Limited
EMA has authorised Fubelv as a biosimilar, with indications across various inflammatory arthritis and psoriasis conditions.
-
EMA approval · 2026-06-09EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG
EU authorization of Rinvoq (upadacitinib) by AbbVie Deutschland for multiple inflammatory indications including rheumatoid arthritis, psoria…